胰岛素-心脏轴上的进展:当前的治疗方法和未来的方向
Alfredo Caturano1,2, Erica Vetrano1, Raffaele Galiero1
1Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, 80138 Naples, Italy.
International journal of molecular sciences
|September 28, 2024
概括
改变生活方式和药物有效地管理胰岛素抵抗和心血管疾病 (CVD),通过准胰岛素-心脏轴. 早期干预可以改善心脏功能,降低2型糖尿病患者的风险.
科学领域:
- 心血管医学 心血管医学
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 胰岛素-心脏轴在心血管疾病 (CVD) 病理生理学中至关重要,特别是在胰岛素抵抗和2型糖尿病中.
- 胰岛素抵抗会引发代谢功能障碍,炎症,氧化应激和动脉动脉生成,导致心力衰竭 (HF) 和其他心血管疾病.
研究的目的:
- 系统地审查针对胰岛素-心脏轴的治疗干预措施,以对抗胰岛素的心血管疾病进行系统审查.
- 评估生活方式修改和药理疗法在改善心血管结果方面的有效性.
主要方法:
- 在PubMed,Scopus和Web of Science的系统文献搜索,搜索过去十年发表的研究.
- 选择标准侧重于胰岛素耐药性,心血管结果和治疗疗效.
- 对治疗胰岛素耐药患者高血压的药理学和新兴疗法的分析.
主要成果:
- 改变生活方式 (饮食,运动) 是管理胰岛素抵抗和改善心血管健康的基础.
- 药物制剂 (甲胺,SGLT2抑制剂,GLP-1RA,DPP-4抑制剂) 通过改善代谢功能和内皮健康来降低心血管疾病风险.
- 新兴疗法,如血管激素受体-尼普利辛抑制剂和心室辅助器件,对高血压管理有希望.
结论:
- 结合生活方式和药理疗法的综合方法对于优化胰岛素-心脏轴至关重要.
- 通过向治疗的早期干预可以改善心脏功能并逆转病态重塑.
- 需要进一步的研究来个性化治疗和了解长期的心血管影响.
相关概念视频
01:22Heart Failure VI: Adjunct Therapies
5
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
5
01:30Heart Failure V: Medical Management
2
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
2
01:15Diabetes: Management and Pharmacotherapy
243
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
243
01:29Cardiomyopathy V: Interprofessional Care
2
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
2
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
395
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
395
01:16Insulin: Dosing Regimen and Adverse Effects
155
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
155